hVIVO (LON:HVO) Announces Earnings Results

hVIVO (LON:HVO) issued its quarterly earnings results on Tuesday. The company reported GBX (0.82) earnings per share for the quarter, Digital Look Earnings reports. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.

hVIVO Price Performance

LON:HVO opened at GBX 6.10 on Wednesday. The firm’s fifty day moving average is GBX 6.81 and its two-hundred day moving average is GBX 7.41. The firm has a market cap of £41.99 million, a price-to-earnings ratio of -7.01 and a beta of 1.69. The company has a debt-to-equity ratio of 38.75, a quick ratio of 1.16 and a current ratio of 1.63. hVIVO has a one year low of GBX 4.30 and a one year high of GBX 11.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.